SAMUEL KOROMA: Open Payments
NPI 1790324960 · WALDORF, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$257 in 12 payments from 5 companies in 2025. Trend: 2023 $127 · 2024 $118 · 2025 $257
Food & beverage: $257
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Janssen Biotech, Inc. | 1 | $26 |
Products named: VRAYLAR, REXULTI, HETLIOZ, CAPLYTA, TREMFYA.
Industry payments across MD — which companies pay providers there.
